# Drugs for Neglected Diseases initiative (DNDi)

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/drugs-for-neglected-diseases-initiative-dndi
Canonical HTML page: https://getbiobrief.com/entity/drugs-for-neglected-diseases-initiative-dndi

## Timeline

- **2026**: Acoziborole Rollout — The first single-dose oral cure begins deployment, enabling 'screen-and-treat' strategies.
- **2018**: Fexinidazole Approval — The first all-oral treatment is approved, requiring 10 days of pills taken with food.
- **2009**: NECT Launch — Nifurtimox-eflornithine combination therapy improves safety but requires complex intravenous administration.
- **1949**: Melarsoprol Introduced — Arsenic-based treatment becomes standard but carries a 5% mortality rate due to toxicity.

## Recent coverage (1 stories)

### Single-Dose Breakthrough: Acoziborole Signals End for Sleeping Sickness
2026-03-16 21:50:22 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

The introduction of acoziborole, the first single-dose oral treatment for Human African Trypanosomiasis (sleeping sickness), marks a pivotal shift in global health efforts. Developed through a non-profit partnership between DNDi and Sanofi, the drug offers a simplified path to disease elimination by 2030.
Full story: https://getbiobrief.com/story/acoziborole-sleeping-sickness-breakthrough-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.